727 related articles for article (PubMed ID: 18422610)
1. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
[TBL] [Abstract][Full Text] [Related]
2. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis in adults with haemophilia.
Hay CR
Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
[TBL] [Abstract][Full Text] [Related]
5. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis in people with haemophilia.
Coppola A; Franchini M; Tagliaferri A
Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
[TBL] [Abstract][Full Text] [Related]
7. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Manco-Johnson M
Haemophilia; 2007 Sep; 13 Suppl 2():4-9. PubMed ID: 17685917
[TBL] [Abstract][Full Text] [Related]
8. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Tagliaferri A; Franchini M; Coppola A; Rivolta GF; Santoro C; Rossetti G; Feola G; Zanon E; Dragani A; Iannaccaro P; Radossi P; Mannucci PM
Haemophilia; 2008 Sep; 14(5):945-51. PubMed ID: 18540895
[TBL] [Abstract][Full Text] [Related]
9. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
10. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A.
Kern M; Blanchette V; Stain AM; Einarson TR; Feldman BM
J Pediatr; 2004 Nov; 145(5):628-34. PubMed ID: 15520762
[TBL] [Abstract][Full Text] [Related]
11. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
12. Prevention of arthropathy in haemophilia: prophylaxis.
Santagostino E; Mancuso ME
Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
[TBL] [Abstract][Full Text] [Related]
13. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs.
Tagliaferri A; Rivolta GF; Rossetti G; Pattacini C; Gandini G; Franchini M
Thromb Haemost; 2006 Oct; 96(4):542-3. PubMed ID: 17003937
[No Abstract] [Full Text] [Related]
14. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
Feldman BM; Rivard GE; Babyn P; Wu JKM; Steele M; Poon MC; Card RT; Israels SJ; Laferriere N; Gill K; Chan AK; Carcao M; Klaassen RJ; Cloutier S; Price VE; Dover S; Blanchette VS
Lancet Haematol; 2018 Jun; 5(6):e252-e260. PubMed ID: 29731369
[TBL] [Abstract][Full Text] [Related]
15. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
16. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Tagliaferri A; Feola G; Molinari AC; Santoro C; Rivolta GF; Cultrera DB; Gagliano F; Zanon E; Mancuso ME; Valdré L; Mameli L; Amoresano S; Mathew P; Coppola A;
Thromb Haemost; 2015 Jul; 114(1):35-45. PubMed ID: 25855376
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the benefits of prophylaxis in the management of hemophilia A.
Hoots WK; Nugent DJ
Thromb Haemost; 2006 Oct; 96(4):433-40. PubMed ID: 17003919
[TBL] [Abstract][Full Text] [Related]
18. Optimizing outcomes for patients with severe haemophilia A.
Pipe SW; Valentino LA
Haemophilia; 2007 Nov; 13 Suppl 4():1-16; quiz 3 p following 16. PubMed ID: 17822512
[No Abstract] [Full Text] [Related]
19. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
20. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
Petrini P
Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
